Clinical trial
A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic…
NCT00073372 · Centocor, Inc., Industry · Terminated
Key facts
| NCT number | NCT00073372 |
|---|---|
| Title | A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) |
| Official title | Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial. |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cerebrovascular Accident, Brain Ischemia, Acute Disease |
| Intervention type | Drug |
| Interventions | Abciximab |
| Enrollment | 808 |
| Start date | Oct 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Nov 21, 2003 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: